[1] |
SIEGEL R L, MILLER K D, WAGLE N S, et al. Cancer statistics, 2023[J]. CA A Cancer J Clinicians, 2023, 73(1):17-48. doi: 10.3322/caac.21763 |
[2] |
TORRE L A, BRAY F, SIEGEL R L, et al. Global cancer statistics, 2012[J]. CA A Cancer J Clinicians, 2015, 65(2):87-108. doi: 10.3322/caac.21262 |
[3] |
Li C, Lei S, Ding L, et al. Global burden and trends of lung cancer incidence and mortality[J]. Chin Med J(Engl). 2023, 136(13): 1583-1590. |
[4] |
Gao S, Li N, Wang S, et al. Lung Cancer in People's Republic of China[J]. J Thorac Oncol. 2020, 15(10): 1567-1576. |
[5] |
Sequist LV, Rolfe L, Allen AR. Rociletinib in EGFR-mutated non–small-cell lung cancer[J]. N Engl J Med, 2015, 373(6):578-579. doi: 10.1056/NEJMc1506831 |
[6] |
YIN J Q, WU Y J, YANG X, et al. Checkpoint inhibitor pneumonitis induced by anti-PD-1/PD-L1 therapy in non-small-cell lung cancer: occurrence and mechanism[J]. Front Immunol, 2022, 13:830631. doi: 10.3389/fimmu.2022.830631 |
[7] |
PAZ-ARES L, CIULEANU T E, COBO M, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2021, 22(2):198-211. doi: 10.1016/S1470-2045(20)30641-0 |
[8] |
SUGAWARA S, LEE J S, KANG J H, et al. Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer[J]. Ann Oncol, 2021, 32(9):1137-1147. doi: 10.1016/j.annonc.2021.06.004 |
[9] |
WU Y L, LU S, CHENG Y, et al. Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced NSCLC: checkmate 078 randomized phase Ⅲ clinical trial[J]. J Thorac Oncol, 2019, 14(5):867-875. doi: 10.1016/j.jtho.2019.01.006 |
[10] |
BORGHAEI H, PAZ-ARES L, HORN L, et al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer[J]. N Engl J Med, 2015, 373(17):1627-1639. doi: 10.1056/NEJMoa1507643 |
[11] |
BRAHMER J, RECKAMP K L, BAAS P, et al. Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer[J]. N Engl J Med, 2015, 373(2):123-135. doi: 10.1056/NEJMoa1504627 |
[12] |
CARBONE D P, RECK M, PAZ-ARES L, et al. First-line nivolumab in stage Ⅳ or recurrent non–small-cell lung cancer[J]. N Engl J Med, 2017, 376(25):2415-2426. doi: 10.1056/NEJMoa1613493 |
[13] |
HELLMANN M D, PAZ-ARES L, CARO R B, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer[J]. N Engl J Med, 2019, 381(21):2020-2031. doi: 10.1056/NEJMoa1910231 |
[14] |
Forde PM, Spicer J, Lu S, Provencio M, et al. CheckMate 816 Investigators. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer[J]. N Engl J Med. 2022;386(21): 1973-1985. |
[15] |
ZHANG W D, GU J J, BIAN C M, et al. Immune-related adverse events associated with immune checkpoint inhibitors for advanced non-small cell lung cancer: a network meta-analysis of randomized clinical trials[J]. Front Pharmacol, 2021, 12: 686876. |